"PATIENTS CAN’T WAIT ANOTHER DECADE" FOR LUNG CANCER SCREENING IN SCOTLAND SAY EXPERTS


The UK Lung Cancer Coalition (UKLCC) will today (10th November 2026) call for faster progress towards a national targeted screening programme in Scotland, as experts, researchers and policymakers gather for its first Scottish regional lung cancer meeting in Stirling.

Lung cancer remains Scotland’s biggest cancer killer in Scotland with 3,651 deaths in 2024, accounting for more than a fifth (22.3%) of all cancer deaths.1 Around half (46%) of lung cancers in Scotland are diagnosed at a late stage (stage 4) when curative treatment is rarely possible.2 Scotland ranks 27th out of 29 European countries for five-year lung cancer survival.3

“Lung cancer screening saves lives,” says Dr John Maclay, Consultant Chest Physician at Glasgow Royal Infirmary and Scottish Lung Cancer Management Pathway Lead. “Scotland risks falling further behind in terms of early detection of the disease unless efforts to roll out the screening programme are accelerated.”

While no formal public Government announcement has been made, Scotland’s ministers have indicated that it could take up to a decade to fully roll out a targeted screening programme for people aged 55 to 74 with a history of smoking, beginning in 2027.

The call comes as targeted lung cancer screening continues to expand elsewhere in the UK.  More than two million people have now attended lung cancer screening appointments in England. Nearly 13,000 lung cancers have been detected through the NHS England programme, with three-quarters diagnosed at an early stage.4 Wales is already well advanced in planning its own lung cancer screening programme.5

“The benefits are clear to see across the border,” said Dr John Maclay. “While research and planning for screening has been progressing for some time in Scotland, patients are understandably concerned about delays in introducing a programme that could help diagnose lung cancer earlier.”

The evidence for screening is now well established. Alongside major international studies, the Scottish LUNGSCOT trial demonstrated that targeted lung cancer screening can be delivered successfully across Scotland, to high-risk individuals – including those living in rural and deprived communities - and can do so cost-effectively.6,7,8

In 2022, the UK National Screening Committee (UKNSC) recommended that all four UK nations move towards implementation of targeted lung cancer screening programmes with inclusion of smoking cessation.9

"Today's meeting brings together clinical leaders from across Scotland who are committed to turning evidence into action and ensuring that screening becomes a reality as quickly as possible," says Dr David Gilligan, chair of the UKLCC and consultant oncologist at Addenbrookes Hospital, Cambridge.

“The UKLCC supports the Scottish Government's willingness to introduce screening, but patients can’t wait a decade for the full benefits to be realised.”

The UKLCC's call for action on screening builds on its Scottish Pathways Matter report, published in November 2023, which set out recommendations to improve lung cancer outcomes across Scotland.10 Chief among these was a call for the Scottish Government and NHS Scotland to implement a targeted national lung cancer screening programme for people at high risk of the disease, in line with recommendations made by the UKNSC.

-ends-

About lung cancer screening:
•    The first large study which showed that lung cancer screening works (the National Lung Cancer Screening Trial) was published in 2011. 6
•    If a screening programme had been implemented at that time, it is estimated that at least 17,000 UK lives would have been saved within 10 years. 11

About the UKLCC
The UKLCC is the UK’s largest multi-interest group in lung cancer. It was set up in 2005 with the founding ambition to tackle poor lung cancer survival outcomes and, specifically, to double five-year survival by 2015, which was effectively achieved. It recently launched its new five-year survival ambition 35 by 35:  35 percent of people alive five years after diagnosis by 2035. The UKLCC’s membership includes leading lung cancer experts, senior NHS professionals, charities, and healthcare companies with an interest in fighting lung cancer. For more information about our work and members, visit: www.uklcc.org.uk
For more details about the UKLCC Lung Cancer Meeting in Stirling on 10th November 2026 visit: https://www.uklcc.org.uk/index.php/uklcc-regional-meeting-scotland

References:
1.    Cancer Mortality. Annual update to 2024 planned revision. Published July 2026. Public Health Scotland. Accessed November 2026: https://publichealthscotland.scot/publications/cancer-mortality/cancer-mortality-in-scotland-annual-update-to-2024-planned-revision/
2.    Optimal Lung Cancer Diagnostic Pathway. Centre for Sustainable Delivery. NHS Scotland. Updated February 2024. Accessed November 2026: https://www.nhscfsd.co.uk/media/iyufsear/nhs-scotland-optimal-lung-cancer-diagnostic-pathway-v12.pdf
3.    Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5—a population-based study Roberta De Angelis, Milena Sant, Michel P Coleman, Silvia Francisci, Paolo Baili, Daniela Pierannunzio, Annalisa Trama, Otto Visser, Hermann Brenner, Eva Ardanaz, Magdalena Bielska-Lasota, Gerda Engholm, Alice Nennecke, Sabine Siesling, Franco Berrino, Riccardo Capocaccia, and the EUROCARE-5 Working Group. Accessed November 2026: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70546-1/abstract
4.    NHSE Monthly Lung Cancer Screening Newsletter dated 16 October 2026. Data from April 2019 to July 2026.
5.    Cabinet Statement, Welsh Assembly 28th June 2025. A National Lung Screening Programme for Wales. Accessed November 2026: https://www.gov.wales/written-statement-national-lung-screening-programme-wales
6.    Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. The National Lung Screening Trial Research Team, New England Journal of Medicine, August 2011. Accessed here October 2026: https://www.nejm.org/doi/full/10.1056/NEJMoa1102873
7.    Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. De Koning et al, J New England Journal of Medicine, January 2020. Accessed October 2026: https://www.nejm.org/doi/full/10.1056/NEJMoa1911793?referrer=https%3A%2F%2Fwww.bing.com%2F
8.    Pilot feasibility study to deliver low-dose CT lung cancer screening in Scotland: descriptive findings from the LUNGSCOT study. Cavers D et al. Accessed October 2026:  https://bmjopen.bmj.com/content/16/9/e120569
9.    UK National Screening Committee Recommendation June 2022. Accessed October 2026: https://view-health-screening-recommendations.service.gov.uk/lung-cancer/
10.    Scottish Pathways Matter. UKLCC November 2023: https://www.uklcc.org.uk/our-reports/november-2023/scottish-pathways-matter
11.    Changing the odds: A Briefing on Lung Cancer Screening in England, Roy Castle Lung Cancer Foundation. Accessed October 2026: https://roycastle.org/about-us/campaigns/changing-the-odds/changing-the-odds-a-briefing-on-lung-cancer-screening-in-england/

For further information, or to arrange an interview, contact:
Lynsey Conway
UKLCC External Affairs
External-affairs@uklcc.org.uk
Or email@lynseyconway.co.uk
Mob: 07778 304233
 


Media Enquiries

For media enquiries, please contact:

Lynsey Conway, UKLCC Communications Consultant
07778 304233 or external-affairs@uklcc.org.uk